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 ABSTRACT 
Purpose: Cancer initiation and progression are the consequence of a complex interplay 
between cancer cells and the tumor microenvironment. Recently, a new global 
transcriptomic immune classification of solid tumors has identified six immune subtypes 
(ISs) (C1-C6) with distinct immunogenomic features significantly associated with 
clinical outcome. The aim of our study was to specifically characterize the ISs in 
colorectal cancer (CRC) patients, and to assess their interplay with the Consensus 
Molecular Subtypes (CMS). 
Patients and Methods: CMS and ISs data, as well as clinical and molecular information 
of CRC patients were obtained from TCGA database27 (N=625). Immune cell 
populations (CIBERSORT, MCP-Counter methods), differential gene expression 
analyses and Gene Set Enrichment Analysis (GSEA) were also performed to characterize 
the immune subtypes in the global CRC population and by CMS subtype. 
Results: Only 5 of the 6 ISs are present in CRC patients, with 2 predominant ISs: the C1 
Wound Healing (77%) and the C2 IFN-γ Dominant (17%) subtypes. CMS1 showed the 
highest proportion of C2 (53%), while C1 was particularly dominant in CMS2 (91%). 
CMS3 had the highest representation of C3 Inflammatory (7%) and C4 Lymphocyte 
Depleted ISs (4%), while C6 TGF-β Dominant cases belonged exclusively to CMS4 
(2.3%). The prognostic impact of ISs in CRC was substantially different from that 
reported for the global TCGA dataset, with best 5-year survival rates observed in C6 and 
C1 patients (100% and 65%, respectively), while C2 and C3 displayed the worst outcome 
(49% and 23%, respectively). C2 tumors had a high density of CD8, follicular helper T 
cells, regulatory T cells, dendritic cells and neutrophils, while C1 was enriched in plasma, 
CD4 T and activated mast cells. Accordingly, expression of several immunomodulatory 
genes, including immune-checkpoints (PDL-1, CTL4, LAG 3), was upregulated in C2 
tumors. GSEA analysis revealed C2 was characterized by a high activation of the immune 
system, apoptosis and DNA repair, as well as mTOR signalling and oxidative 
phosphorylation, while C1 was more dependent of metabolic pathways such as glycolysis 
and pyruvate metabolism.  
 
Conclusion: ISs identify distinct immune profiles within CMS subgroups with relevant 
clinical and biological implications and may therefore be a valuable tool to improve 
tailored therapeutic interventions in CRC patients.  
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MOTIVATION 
Colorectal cancer (CRC) is the second leading cause of cancer-related death 
worldwide and the first taken into account both genders, with 15,410 deaths in 2017 and 
an estimation of 44,937 new cases in Spain according to the Sociedad Española de 
Oncología Médica (https://seom.org). CRC clinical management is primarily based on 
tumor location and extent of the disease, with a very limited repertoire of molecular 
biomarkers to guide personalized patient care. CRC is, however, a heterogeneous disease 
with widely variable clinical outcomes, both in terms of prognosis and drug response. 
Mainly part of this clinical variability is due to tumor diversity that is also reflected at 
genomic level where two major groups can be identified with relevant predictive and 
prognostic implications: i) hypermutated tumors (mutation rates > 12xE06 bp), 
accounting for about 15% of colorectal carcinomas which are associated with a rich 
immune cell infiltration, favourable prognosis in early-stage disease, poor prognosis in 
the metastatic setting but a good response to immune checkpoint inhibition and ii) non-
hypermutated tumors that are globally associated with a worse prognosis and a poor 
response to immunotherapy1,2. Despite the genomic heterogeneity in CRC, the only 
genomic biomarkers that are currently well established as standard guidelines are RAS 
mutation to avoid therapies with anti-EGFR drugs and MSI or deficient MMR to select 
patients for treatment with immune checkpoint inhibitors1–5. 
Molecular classification based on transcriptomics data is a tool that is taking importance 
at scientific and clinical level and provide new ways of clinical cancer research6–8. This 
technology combines information of several genes that are expressing, not only in tumor 
cells, but also in those that are part of microenvironment. It is well known that 
microenvironment plays an important role determining the patient prognosis and response 
to therapies. In this context, transcriptomics classification encompasses not only tumor 
cell component, but also immune and stromal components of cancer. Thus, to make 
classifications based on intrinsic gene expression profiles more intimately linked to tumor 
phenotype and therefore more closely related to clinical behaviour9–14. In 2015, the 
international Colorectal Cancer Subtyping Consortium (CRCSC) proposed a unified 
transcriptomics classification that identified four biologically distinct Consensus 
Molecular Subtypes (CMS)15. Although CMS classification show substantial differences 
at abundances of immune populations and expression of immune related genes, this 
classification is based on a general transcriptomics data. In contrast with CMS 
classification, Thorsson and colleagues have developed a clustering system based on 
transcriptomics data but focussing only on genes related to immune system16. Nowadays, 
the study of tumors in an immune perspective have acquired high clinical relevance due 
to the great results that immunotherapy has achieved in some patients. Currently the 
microsatellite instability seems to be the best biomarker to select CCR patients who may 
benefit from this kind of treatment1. However only one third of these patients response to 
immunotherapies17.  This situation makes necessary to develop a better stratification 
system to select patients for immunotherapy treatments, being microenvironment status 
one of the elements that could affect more. In this work we have studied the immune 
subtype classification in CRC in depth, obtaining results that suggest it possible relevance 
in the patients stratification based on in the tumor microenvironment and consequently, 
it’s importance in the patient selection to immunotherapy.  
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1. INTRODUCTION 
1.1 Epidemiology and origin of cancer 
Cancer has cost 9.6 million of lives in 2018, being a leading cause of death 
worldwide (https://www.who.int), in our country the number of cases estimated in 2017 
was 228.482 but to 2.035 is expected around 315.400 new cases (https://seom.org/). This 
pathology involves a great number of diseases that could affect different tissues. The 
common pattern of these pathologies is the accumulation of alterations at genomic level 
that promote the uncontrolled and aggressive growth of the cells, originating a malign 
tumor. Those cells can acquire selective advantage, allowing its perpetuation and the 
development of invasive and migration skills which cause metastasis events18.  
The way to obtain the genomic alterations makes etiology of cancer is diverse. It 
can develop due to inheriting an alteration from one of the progenitors, what is known as 
hereditary cancer. Nevertheless, hereditary cancer involves only between 5-10% of 
patients, so most of the alterations are somatic (genomic alteration generated in non-
germline cell), developing what it is called sporadic cancer19. Inside of sporadic cancer 
we can found several factors that influence the development of cancer. It could be 
endogenous (hormones and metabolites) or exogenous (alcohol, tobacco, drugs, radiation 
viruses)20.  
In the last decade, several international cancer genomes research consortiums 
have been established with the aim of comprehensively characterize the genomic 
alterations of several tumors. An example is The Cancer Genome Atlas (TCGA) 
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consortium (http://www.cancergenome.nih.gov/) which has characterised over 20,000 
primary cancer from generating the biggest database with -omics cancer information. This 
meant over 2,5 petabytes of free information available for the research community 
divided into genomics, epigenomics, transcriptomics, proteomics and clinical data. 
TCGA also allowed the creation of PanCancer, an international research project called 
focused on the study of the differences among genomic and molecular alterations across 
diverse tumor types21. 
The information provided by the cancer genome sequencing projects have allowed 
to reveal ‘driver genes’, that is, those altered genes which confer a selective growth 
advantage to tumor cells22. It has been defined 2 types of driver genes 23. 
● Proto-oncogenes: Genes that are related to survival and cell division. The 
alteration in these genes affect their own regulation, making them constitutively 
activated. Usually only one altered allele of these genes is needed to generate the 
carcinoma cell phenotype.  
● Tumor suppressor genes: Genes that prevent the tumor development by 
modulating cell cycle progression and apoptosis. Alterations of these genes 
generate the loss of function of the protein, avoiding the correct regulation of cell 
growth. In this case both alleles must be altered to show the tumor phenotype.  
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1.2 Molecular basis of colorectal cancer  
CRC is the neoplasia with more incidence in the world considered both genders. 
Furthermore, is the second dead cause in men and women separately. Nevertheless, the 
early detection using better screening protocols has entailed the 5-year survival 
improvement on CRC patients, but a 25% of patients still develop metastasis whose 
survival rate at 2 years around 35%24.  
As other types of cancer, the origin of CRC is associated with the mutation 
accumulation obtained by inheriting or by exogenic and endogenic factors. Thus, promote 
the passage from normal epithelium to invasive carcinoma25. One of the exogen factors 
more related to CRC development is the diet. Some eating habits that may influence to 
develop CRC cancer are the triglycerides and red meat excess consumption joined to low 
presence of fibber, D vitamin and phosphates on diet. Besides, some metabolites 
generated by bacterial flora have been related to the colorectal carcinogenesis26,27. The 
main driver genes in CRC are the proto-oncogenes KRAS and BRAF and the tumor 
suppressors APC, PTEN and TP53 which alteration causes the tumor progression19,28 
CRC tumor can be classified into two main groups from a genomic perspective; 
hypermutated tumors and no hypermutated tumors. Three-quarters of hypermutated 
tumors have microsatellite instability (MSI), generally due to hypermethylation and 
silencing of the MLH1 promoter, and one-quarter have somatic mutations in mismatch-
repair (MMR) or polymerase ε (POLE) genes. On the other hand, the majority of sporadic 
colorectal tumors (~85%) present chromosomal instability (CIN) and are generally non-
hypermutated. The pattern of genomic and epigenomic events, thus, substantially differ 
in hypermutated versus non-hypermutated tumors28. 
 
4 
 
1.3 Immunotherapy in CRC 
Immunotherapy is defined as cancer therapies, which mechanism of action 
consists in stimulating immune response to tumors. There are different types of 
immunotherapies such as CART-t cell therapy, cytokine therapy or cancer vaccines, but 
the most used in cancer are immune checkpoint inhibitors29. Immune checkpoints are 
control proteins present on the surface of the cell. The union between this proteins and T 
cell ligands promote the inhibition of this lymphocytes. This mechanism is necessary in 
the body to avoid the development of autoimmune reactions but tumors use it to escape 
from the immune system. The use of molecules that block this unions have raised in the 
recent years because of the great observed benefit in some patients. However, the lack of 
response in others makes necessary the correct stratification of the patients to decide to 
treat them with immune checkpoints inhibitors29. In CRC, immunotherapy was approved 
in 2017 but only for heavily mutated tumors that are mismatch-repair-deficient (dMMR) 
or have high levels of microsatellite instability (MSI), since patients with tumors that do 
not accomplish these requirements show resistant to these drugs. However, the recent 
clinical trials establish that the response rate of the tumor with this characteristic is 
between 50 – 69%, depending on study4. 
 
1.4 Cancer transcriptomics 
Transcriptomics technologies are the techniques used to study an organism’s 
transcriptome, the sum of all of its RNA transcripts30. Currently, there are two main high-
throughput technologies which are used to obtain transcriptomics data: i) gene expression 
microarrays and ii) RNA-seq. Gene expression microarrays were born in 1995, this 
technology is based on hybridization between the cDNA of a sample (RNA that has been 
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retro-transcribed to DNA) and fluorescent probes that, usually, represent the known 
transcriptome30. Gene expression microarrays allowed to quantify expression level of 
each gene (represented by probes) were being displayed in the sample, what meant a great 
step in the research of the biology of cancer. Some gene expression microarray limitations 
include the need of an a priori knowledge of the transcriptome sequence to design the 
probes, cross-hybridization events and need a high amount RNA30. 
RNA-seq consist on sequencing fragments of cDNA that calls reads. These reads 
are aligned with a transcriptome reference. Reads which belong to the same gene are 
quantified and normalized considered the gene size and the number of total reads into 
RPKM (reads per kilobase million) or FPKM (fragments per kilobase million). Finally, 
the reads per gene are obtained in all samples giving the gene level expression30. 
Differences between these two transcriptomics technologies have been discussed in other 
publications30,31. 
The most usual applications of transcriptomics high-throughput technologies are 
focused on comparing two conditions (e.g. tumor versus control), obtaining the 
differentially expressed genes between them 30, performing functional analysis32 and 
establishing molecular classifications6,8,15.  
 
1.5 Transcriptomics based classification systems in CRC. 
CRC in one of the tumors which more people have studied to make a classification 
system based on transcriptomics data, existing eight different classifications before 
20159–14. These different classification systems have some similarities, but the lack of 
consistency among them triggers the creation of the international Colorectal Cancer 
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Subtyping Consortium (CRCSC)15. The CRCSC developed the consensus molecular 
subtypes, based on the previous classification systems. Consensus molecular subtypes 
(CMS) classification distinguish among four different consensus molecular subtypes: i) 
CMS1 (MSI immune subtype, 14% of early-stage tumors), characterized by tumors 
hypermutated, hypermethylated, enriched in BRAFV600E mutations and with a strong 
immune activation; ii) CMS2 (canonical subtype, 37% of early-stage tumors), includes 
tumors with high chromosomal instability and somatic copy number alterations, with a 
marked upregulation of WNT and MYC signalling, and higher expression of epithelial 
features; iii) CMS3 (metabolic subtype, 13% of early-stage tumors), encompasses 
epithelial tumors with metabolic deregulation and enriched in KRAS-activating 
mutations and iv) CMS4 (mesenchymal subtype, 23% of early-stage tumors), defined by 
a strong activation of epithelial-mesenchymal transition (EMT), angiogenesis, 
transforming growth factors (such as TGF-β) and stemness pathways, that is the CMS 
with the worst relapse-free and overall survival rates15. 
The CMS classification is the most robust classification currently available for the 
stratification of CRC and has showed to have a prognostic value. On an immune point of 
view, CMS1 is the subtype with more abundance of cytotoxic T cells (CD8+) and 
macrophages (CD68) cells followed by CMS4, which also is characterised by having a 
high level of stromal and fibroblast cells. On the other hand, CMS2 and CMS3 subtypes 
are cold tumors with less presence of immune populations. CMS1 also present more 
expression of chemokine coding genes related to T cell activation (CXCL9, CXCL10, 
CXCL16, IFNG and IL15) and genes involved in T cell inhibition (PDCD1, CD274, 
PDCD1LG2, CTLA4 and LAG3). However, tumors which belong to CMS4 subtype  
have more activated genes with important role in angiogenesis(VGFB, VEGFC, 
PDGFC), genes related with immunosuppression (CXCL12 , TGFB1, TGFB3 and 
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LGALS1) and genes expressed in complement system cells (C15R, C1R, C3, C3AR1, 
C5AR1, CT, CFO, CFH and CF1)33. 
 
1.6 Immune subtype (IS) classification  
The relationships between the immune system and cancer have acquired an 
important impact in the recent years. Currently there are several researches that establish 
it clear prognostic value and the effect to the response of several anti-cancer therapies34. 
With this motivation Thorsson et al have developed an IS classification in PanCancer16. 
This IS classification is made over more than 11.000 patients from all 33 non-
haematological TCGA cancer types. They used a scored collection of 160 different 
immune expression signatures with single sample gene set enrichment (ssGSEA) to 
identify modules of immune related gene sets. Then they chose five signatures where each 
one represents a module and they made a clustering using these scores. As a result, they 
identified 6 distinct immune subtypes (C1-C6) described below, characterized by relevant 
differences in lymphocyte or macrophage signatures, T helper type 1 (Th1) : T helper 
type 2 (Th2) ratio, expression of immunomodulatory genes, intratumoral heterogeneity, 
neoantigen load, aneuploidy, cell proliferation and prognosis16:  
- Wound Healing subtype (C1) showing an elevated expression of angiogenic 
genes, a high proliferation rate and a low Th1:Th2 ratio related to the adaptive 
immune infiltrate.   
- IFN-γ Dominant subtype (C2) presenting a high proliferation rate too, the 
highest intratumoral heterogeneity, the highest Macrophage type 1 (M1): 
8 
 
Macrophage type 2 (M2) polarization and CD8+ T cell population, and the 
greatest TCR diversity.  
- Inflammatory subtype (C3) defined by elevated Th17 and Th1 genes, low to 
moderate proliferation, lower levels of aneuploidy, higher somatic copy number 
alterations and the most favourable prognosis.  
- Lymphocyte Depleted subtype (C4) presenting moderate cell proliferation and 
intratumoral heterogeneity, and a prominent macrophage signature with Th1 
suppressed and a high M2 response; consistent with these features, it was 
associated with a poor outcome.   
- Immunologically Quiet subtype (C5) displays the lowest lymphocyte and 
highest macrophage responses, dominated by M2 macrophages, and had low rates 
of proliferation and heterogeneity.  
- TGF-β Dominant subtype (C6) was a small group of mixed tumors with the 
highest TGF-β signature and a high lymphocytic infiltrate with a balanced 
Th1:Th2 ratio. Together with C4, C6 was associated with the worst prognosis. 
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2. OBJECTIVES 
The main goal of this work is to study the clinical value of combining IS and CMS 
classifications in CRC (Figure 1). To achieve this goal, we have used CRC TCGA data 
to study the clinical, molecular and immune differences among immune subtypes in the 
whole cohort and using each CMS cohort separately. 
1. To study the relationship between CMS and Immune subtype classification 
in CRC.  Proportion of Immune subtypes in each CMS and vice versa have been 
established to look for an enrichment in any of the two directions. 
2. To analyse the association between clinic-pathological variables and Immune 
subtypes in CRC. Clinic-pathological variables have been studied to look for 
associations with any of the Immune subtypes in the general cohort and in each 
CMS. 
3. To observe differences in the proportion of distinct immune populations 
among immune subtypes. We have analysed differences in the abundances of 
the distinct immune population cells, using the whole cohort and in each CMS. 
4. To obtain the differentially expressed genes and the enriched pathways 
among the two principal immune subtypes in CRC. We have assessed the 
genes and biological pathways in which the two main immune subtypes are 
different. We are going to use all patients together and distinguish them by CMS.  
5. To investigate the prognostic and potential predictive power of immune 
classification in CRC. We have analysed overall survival data to study possible 
prognostic value of Immune subtypes in CRC. Besides, we have examined the 
expression of important immunomodulator and immunotherapy biomarker genes. 
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Figure 1:  Summary of  the main objectives and steps encompassed in this project. CMS 
and IS classifications are integrated in CRC patients in order to study the overlapping 
between them. Furthermore, differences in principal clinical variables, immune 
population abundances, genes expression, prognosis and potential predictive power are 
assessed among immune subtypes in the whole cohort and in each CMS. 
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3. MATERIAL AND METHODS 
 3.1 Study population and datasets 
3.1.1. Study population 
The study population included all colorectal cancer patients from TCGA database 
(N= 625)35. We have selected those patients with available information on the IS as per 
the new immune classification recently developed by Thorsson et al (N=597)16. 
Information about IS were obtained from the Immune Subtype Clustering github 
repository (https://github.com/Gibbsdavidl/Immune-Subtype-
Clustering/tree/master/shiny-app/Immune-Subtype-Clustering). Information on 
microsatellite instability, CIMP status and CMSs (N=573) was downloaded from the 
Colorectal Cancer Subtyping Consortium (CRCSC) Synapse 
(https://www.synapse.org/#!Synapse:syn2623706/wiki/67246)15. (Figure 2)  
To obtain clinical and genomic data of TCGA patients, different data portals have 
been used. Clinical and RNA-seq data was acquired from the GDC colon and rectal Xena 
Browser data set (https://xenabrowser.net)36. TCGA data was also downloaded from 
cBioportal (http://www.cbioportal.org/datasets) where CNV data (N=614) and mutation 
annotation format (MAF) files with gene mutation status  (N=526) were obtained37. 
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3.1.2. Datasets 
Different data from CRC cohort of TCGA project was used for this work such as: 
● Clinical data: Matrix where patients are rows and clinical information are 
columns. Clinical data used for each analysis are detailed in Supplementary 
Tables 1 and 2.   
● RNA-seq data: Matrix with log2 transformed read counts per gene. Genes are in 
rows while samples are in columns. Read counts belong to TCGA version 3 data 
and is obtained by Htseq software38. Some data processing was made before using 
the datamatrix: 
1. Log2 transformation was reverted from data prior to data analysis.  
2. Samples from metastasis were deleted from expression matrix. 
3. Twenty five repeated genes were collapsed using the row with more 
variance among all samples. 
● CNV data: Data generated by GISTIC software obtained39. CNV data was 
analysed considering only deep amplifications for oncogenes 
(log2CopyNumber>1) and deep deletions for tumor suppressor genes 
(log2CopyNumber<1). 
● Mutation data: Matrix where each row represents one mutation with further 
information such as sample, gene, mutated allele, reference allele, chromosome 
position etc. Synonym mutations, and non-coding exon and intron mutations were 
filtered out from the MAF file prior to mutation detection and hypermutation class 
identification. Hypermutation phenotype threshold was established using a 
mutation rate>12 per 106 bps as previously described35. Then a matrix with 
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samples as rows and genes of interest as columns was made with mutation 
information where 1 is mutated and 0 is non mutated. It is important to highlight 
that only V600E mutation was considered for the analysis of BRAF mutations. 
The mutated genes analysed appear in Supplementary Tables 1 and 2.   
 
3.2 Clinical and molecular data analyses 
Descriptive statistics were used to characterize the most relevant clinical 
parameters. Fisher’s exact test was applied to obtain the associations of categorical 
variables (clinical features and mutations) and colorectal cancer subtypes by using R 
software40. P-values were obtained by Monte Carlo simulation with 104 replicates.  
 
3.3 Overall Survival  
Overall Survival (OS) is the elapsed time from the date of diagnosis to the date of 
death of any cause or patient’s last clinical consultation in alive patients. Survival function 
was estimated according to the Kaplan-Meier method41 while differences in survival 
distributions between groups were assessed using the log-rank test42 (Figure2). Cox 
proportional hazard univariate and multivariate analysis were also conducted, including 
relevant known clinical and pathological prognostic factors (age, gender, site of primary 
tumor, tumor histology and stage at diagnosis) as well as the IS and CMS classifications. 
Finally, the Cox proportional risk regression model was fitted to data to estimate the 
independent prognostic value in terms of OS and confound variables were analysed. The 
basic assumptions of the model were evaluated employing proportional hazards. 
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3.4 Immune cell population analysis. 
Immune cell abundance estimation was generated applying deconvolution-based 
software to RNA-seq data. These programs use a precomputed matrix with information 
about transcriptomic markers of different immune cell population and extract this signal 
from a mixture RNA-seq data from bulk tissue (Figure2). The deconvolution software 
employed were CIBERSORT43  and MCP counter33: 
 
● CIBERSORT: CIBERSORT is a deconvolution method that estimate relative 
proportion of 22 cell type, using a leukocyte signature matrix and a linear support 
vector regression approach. Relative proportion of the 22 immune cell types 
analysed by CIBERSORT were obtained from supplemental material of The 
Immune Landscape of Cancer publication. Relative percentages were then 
multiplied by Leukocyte fraction to obtain Absolute fraction16. Statistical analysis 
to assess differences in the overall fraction of immune cell types between ISs were 
performed applying pair-wise Wilcoxon Rank test using R software40. 
● MCP counter: MCP counter is a deconvolution method which calculates the 
absolute abundance of 11 cell population, using specific transcriptomic markers. 
Immune and stromal cell populations were estimated by MCP-counter33, using the 
upper quartile normalized and log2+1 transformed RNA-seq data. Statistical 
differences between ISs were evaluated using pair-wise Student’s t test  in R 
software40.  
 
Data related to tumor mutation burden (TMB), B cell receptor richness (BCR) and 
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T cell receptor richness (TCR) were consulted in supplemental material of The Immune 
Landscape of Cancer publication and differences among immune subtypes were applied 
using Wilcoxon rank test in R software40. ComplexHeatmap R package44 and z-score 
values obtained from all samples were employed to generate immune population and IS 
heatmaps.  
 
3.4 Differential expression and gene set enrichment analysis   
Differential expression analysis between wound healing and IFN-γ ISs was 
performed using Bioconductor’s DESeq2 package45. To account for multiple hypotheses 
testing, the estimated significance level (P-value) was adjusted using Benjamini & 
Hochberg False Discovery Rate (FDR) correction46. Genes with FDR <0.05 were selected 
as differentially expressed between both subtypes. Prior to differential expression 
analysis, genes showing flat patterns (inter quartile range<0.5) across patients were 
filtered out from DESeq2 normalized matrix48 (Figure2).  CMS subtype and batch number 
available in clinical data were used as covariates in differential expression analysis in 
order to avoid potential confusion effects in analysis involving all patients. Gene 
annotations were obtained by biomaRt R package47 and KEGG pathways were obtained 
from KEGG.db package48 . Coincident genes found in all analysis performed were 
retrieved using UpSetR package49 . 
 
Gene set enrichment analysis was computed with ssGSEA algorithm implemented 
in Bioconductor’s gsva R package50 , using upper quartile normalized RNA-seq data and 
gene sets of Hallmarks and KEGG collections available in MSigDB 
(http://software.broadinstitute.org/gsea/msigdb/index.jsp). Differentially activated 
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pathways between the two predominant ISs, Wound Healing and IFN-γ Dominant sub 
types, were assessed performing the Student’s T test implemented in RVAideMemoire51 
with 1000 permutations to the gene sets enrichment scores (ES). The resulting p-values 
were adjusted for multiple comparisons by Benjamini-Hochberg’s FDR correction46 
(Figure2). ES median Z-scores from significant differentially enriched pathways among 
Wound Healing and IFN-γ Dominant subtypes were plotted in a heatmap 
using  ComplexHeatmap R package44.  
 
 
3.5 Analysis of immune modulator genes  
Gene expression analysis: only those samples with RNA-seq data available were 
employed for immune modulator genes expression analysis (N=590). To this end, we 
applied upper quartile normalization and log2(expression+1) transformation for each of 
the 75 immune modulator genes with respect to each immune subtype. Then we 
performed a Kruskal-Wallis or Wilcoxon signed-rank test depending on the number of 
immune subtypes considered in each analysis. The resulting p-values were adjusted for 
multiple comparisons by Benjamini-Hochberg’s FDR correction. ComplexHeatmap R 
package was employed to build heatmaps using Z-score median values from all immune 
modulator genes44. 
CNV analysis: only samples with CNV data were included in this analysis 
(N=432). Immune modulators CNV analysis was carried out considering deep 
amplifications (log2CopyNumber>1), shallow amplifications (log2CopyNumber=1), 
shallow deletions (log2CopyNumber=-1) and deep deletions (log2CopyNumber<-1). We 
calculated the differences between observed and expected frequencies for every immune 
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modulator gene in each immune subtype. Heatmaps were obtained using 
ComplexHeatmap R package44. 
3.6 Supplementary material  
Supplementary figures, tables and results are available at http://bit.ly/2Zz3Frh 
 
 
Figure 2: Resume of the material and methods used in this project. Consensus Molecular 
Subtypes and Immune subtypes were obtained from TCGA patients cohort. Clinical, survival and 
transcriptomics data of these patients were analysed.  Transcriptomics data was used to obtain 
immune cell population applying deconvolution methods (CIBERSORT and MCP counter), 
differentially expressed genes (DESeq2) and differentially enriched pathways (ssGSEA + t-
Student test).  
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4. RESULTS 
4.1 Overview 
In this project we perform the integration of CMS and IS transcriptomics 
classification system (Figure 3). Such analysis allow us to obtain the following results: 1) 
the Immune Subtype distribution in the global CRC population and by CMS (see section 
4.2), 2) clinical and pathological features of colorectal cancer patients by immune subtype 
(section 4.3), 3) the prognostic impact of immune subtypes in colorectal cancer (section 
4.4), 4) immune and stromal cell population in distinct   immune subtypes of CRC patients 
(section 4.5), 5)expression of immunomodulatory genes (section 4.6) 6) genes and 
pathways differentially expressed among the principal immune subtypes (section 4.7).  
 
 
Figure 3: Project and results overview.  
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4.2 Immune Subtype distribution in the global CRC population and by CMS  
 
First, we assessed the distribution of immune subtypes in the global CRC 
population (N=573). We found that the 2 predominant ISs in CRC were the C1 Wound 
Healing subtype, identified in 459 samples (77%), and the C2 IFN-γ Dominant subtype, 
present in 103 samples (17%). The rest of ISs were barely present in CRC patient as we 
saw in C3 Inflammatory subtype (18 samples, 3%), C4 Lymphocyte Depleted subtype 
(13 samples, 2%) and C6 TGF-β Dominant subtype (4 samples, 0.7%) subtypes. Of note, 
no CRC sample belonged to the C5 Immunologically Quiet IS (Supplementary Table 1).  
Then, we evaluated the crossover between CMS and IS classifications (Figure 4, 
Supplementary Tables 3 and 4). The 2 main CRC ISs, C1 and C2, were present in all 
CMSs but their relative distribution is not equal in all CMSs (Figure 4A, Supplementary 
Table 3). In fact, the C1 Wound Healing IS was markedly dominant in CMS2 (91%) but 
far less common in CMS1 (46%) tumors, whereas the proportion of C1 Wound Healing 
in CMS3 and CMS4 tumors was similar to the average observed for the overall CRC 
population (77-78%). On the contrary, the C2 IFN-γ Dominant was the most common IS 
observed in CMS1 tumors (53%) and was under-represented in CMS2 tumors (8%), 
whereas the proportion of the C2 IFN-γ Dominant in CMS3 and CMS4 tumors was 
slightly higher (11-13%). Other ISs were barely present in CMS1 and CMS2 tumors 
(Lymphocyte Depletion subtype – 1 patient in each CMS group; Inflammatory subtype – 
not represented in the CMS1 group, 2 patients in the CMS2 group; no TGF-β Dominant 
cases).  The immunological landscape of CMS3 and CMS4 was slightly more diverse: 
they have more patients from C3 Inflammatory subtype (7% and 6%, respectively), as 
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compared to CMS1/2. Besides, CMS3 had the highest representation of the C4 
Lymphocyte Depleted subtype (4%), and all 3 cases with the TGF-β Dominant phenotype 
belonged exclusively to the CMS4 subgroup (2.3%). Then, we analysed the distribution 
of CMS groups by immune subtype (Figure 4B, Supplementary Table 4). We found that 
the C1 Wound Healing subtype is enriched in CMS2 and CMS4 groups (46% and 25%, 
respectively) and the remaining classified samples were distributed between CMS1 (8%) 
and CMS3 (13%). Eight percent of the C1 Wound Healing samples were not classifiable 
in any CMS group. The C2 INF-γ Dominant samples are enriched in CMS1 (41%), 
although a notable proportion of patients belonged to other CMS groups (17% were 
CMS2 and 18% CMS4), and a small fraction was classified as CMS3 (9%). The 
distribution of CMS in other less common IS in CRC is less reliable due to the limited 
number of samples within each category. However, a relevant proportion of Inflammatory 
and Lymphocyte Depleted samples were classified as CMS3 (28% in both cases) and 
CMS4 subtypes (44% and 18%, respectively). The remaining samples of the 
Inflammatory subtype were classified as CMS2 (11%), while the rest of Lymphocyte 
Depleted samples were equally distributed in the CMS1 and CMS2 groups (9% each). 
Finally, all 3 TGF-β Dominant samples were classified as CMS4 (100%).  
In summary, these results indicate that the subtypes most frequently found in CRC 
were Wound Healing and INF-γ Dominant subtypes while Inflammatory, Lymphocyte 
Depleted and TGF-β Dominant are less represented. Furthermore, not all CMS has the 
same proportions of IS, being CMS1 the most differentiated with a high proportion of 
INF-γ Dominant samples. 
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A                                                                                    B 
 
Figure 4: Interplay between Immune subtypes and CMS in CRC: A) Distribution of ISs in CMS1, 
CMS 2 CMS3 and CMS4 subtypes. B) Distribution of CMSs in Wound Healing, IFN-γ dominant, 
Inflammatory and TGF-β dominant subtypes. 
 
4.3 Clinical and pathological features of colorectal cancer patients by immune 
subtype 
Main clinical, pathological and molecular characteristics by immune subtype in 
the global CRC study population are depicted in Figure 5 and detailed in Supplementary 
Table 4. In summary, we found that C2 IFN-γ Dominant is enriched in tumors located in 
the right colon, while C1 Wound Healing and C3 Inflammatory ISs were frequently 
encountered in left-sided tumors. No significant association with ISs were observed by 
gender or stage at diagnosis. All immune subtypes presented a similar proportion of 
KRAS mutations, with the exception of the TGF-β Dominant IS, were no KRAS 
mutations were identified. On the contrary, enrichment of BRAF mutations was observed 
in the IFN-γ Dominant subtype (25%), and also in the Lymphocyte Depleted (17%) and 
TGF-β Dominant (33%) subtypes, although these figures are not too reliable due to the 
small sample size in these last two subgroups. MSI, CIMP and hypermutated phenotypes 
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were consistently more frequently found in the IFN-γ Dominant subtype. The incidence 
of APC mutations was highest in C1 Wound Healing, and TP53 mutations observed in 
>50% of C1 Wound Healing or C2 INF- γ Dominant ISs but were less common y C3 
Inflammatory and C4 Lymphocyte Depleted ISs. However, we repeated this analysis 
using only patients that belong to the same CMS group and no significant relationship 
were found in any of the previous associated variables (Supplementary Figures 2-5 and 
Supplementary Tables 5-8). The incidence by immune subtype of the 10 most frequently 
genetic alterations in hypermutated and non-hypermutated tumors were provided in 
Supplementary Table 9. Connections observed between different clinical, pathological 
and molecular characteristics and CMSs are consistent with those previously reported 
(Guinney et al., 2015) (Supplementary Figure 1 and Supplementary Table 3). 
These results suggest that the associations found between clinical features and ISs 
are brought by the different proportion in CMSs, but not by itself. 
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Figure 5: Clinicopathological characteristics of colorectal cancer patients according to immune 
subtypes.  Bar plots showing the proportion of gender, tumor  stage, localization  of primary 
tumor, histology, KRAS, NRAS, BRAF, APC and TP53  mutations, hypermutated phenotype, 
microsatellite instability and CpG island methylator phenotype  (CIMP)  in  immune  subtypes  
C1  (wound  healing),  C2  (IFN-γ  dominant),  C3 (inflammatory), C4 (lymphocyte depleted) and 
C6 (TGF-β  dominant). Number of patients with specific clinical information for each immune 
subtype is detailed below the bar plots. 
 
4.4 Prognostic impact of immune subtypes in colorectal cancer  
The OS analysis in CRC patients showed that the impact of the different ISs in 
survival significantly (P= 0.02) differed from that reported for the overall TCGA dataset, 
which included 33 different solid tumor types16 (Figure 6A). Indeed, in the CRC study 
cohort, patients with the TGF-β Dominant and Wound Healing ISs showed better 
prognosis than other subtypes (5-year OS rates of 100% and 65%, respectively), whereas 
IFN-γ Dominant and Inflammatory were the subtypes associated with the worse outcome 
(5-year OS: 49% and 23%, respectively) (C2 vs C1, HR 1.59, P=0.004; C3 vs C1, HR 
2.77, P=0.02) (Figure 6B, Supplementary Table 10). However, the lack of patients in 
some of the ISs makes impossible to draw practical conclusions. Similar trends were 
observed when we analysed the prognostic impact of immune subtypes within each CMS 
subgroup (Supplementary Figure 6 and Supplementary Table 10). Cox multivariate 
regression analysis showed that the immune subtype classification was significantly 
associated with survival in CRC patients, independent of other well established 
prognostic factors such as age, stage at diagnosis, or localization of primary tumor 
(Supplementary Table 11), showing that the immune phenotype had a significantly 
greater influence on OS than CMS (not significant in the multivariate analysis).  
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Figure 6: Impact of immune subtypes on survival of colorectal  cancer  patients. Patients at risk 
at the corresponding time point and survival rates at five years in each subtype are provided.  P-
value was calculated by log-rank test. CMS: Consensus Molecular Subtypes. 
 
 
4.5 Immune subtypes of CRC patients show distinct immune and stromal cell population 
patterns 
Different patterns for immune and stromal cell populations abundance were found 
among immune subtypes in CRC patients. The most relevant differences were identified 
between the two major subgroups, Wound Healing (N= 452) and IFN-γ Dominant 
(N=103). Thus, tumors with IFN-γ Dominant profile presented a strong expression of 
CD8+, CD4+ activated, follicular helper T cells, regulatory T cells, memory B cells and 
M1 macrophages. Moreover, high levels of natural killer cells (NKs), dendritic cells, 
neutrophils and M2 macrophages were also found in this subtype (Figure 7A and B). In 
contrast, Wound Healing subtype tumors presented higher proportions of memory CD4+ 
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(Figure 7A). No differences were found in endothelial cells and fibroblasts abundance 
between these two groups, although the proportion of these populations was high in the 
four samples belong to TGF-β subtype (Figure 7B). Next, we analysed the distribution of 
immune and stromal cell populations by immune subtype within each CMS group. The 
distribution of all cell types analysed was similar in the CMS1 group, with significant 
differences observed between the Wound Healing and IFN-γ Dominant subtypes, except 
neutrophils and dendritic cells which do not have significant differences. (Supplementary 
Figure 7). In CMS2 immune and stromal cell proportions variate less between these two 
subtypes, being even more diluted in CMS3 and CMS4 (Supplementary Figures 8-10). 
These results show that IFN-γ is the subtype with more immune cell abundances 
which are also maintained in CMS1. 
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Figure 7: Immune and stromal differential signatures among immune subtypes.  A)  CIBERSORT 
heatmap showing the distribution of lymphoid and myeloid lineages by immune subtype.  
*P<0.05, **P< 0.01, ***P<0.001, **** P<0.0001 using Wilcoxon test.  B) MCPcounter heatmap 
showing the estimated abundance of several immune and stromal-cell populations in CMS1 
colorectal cancer patients by immune subtypes.  *P<0.05, **P< 0.01, ***P<0.001, **** 
P<0.0001 using Student’s t-test. 
 
 
4.6 Immune subtypes of CRC patients show differential expression of immunomodulatory 
genes  
We examined gene expression, amplification or deletion of a large set of 
immunomodulators (IMs) across immune subtypes. Upregulation of several genes with 
different immunomodulatory functions were found in the IFN-γ Dominant subtype, such 
as CD80 (FDR=1.69E-12), CD28 (FDR=5.20E-09), CD274 (PDL-1) (FDR=6.80E23), 
CXCL10 (FDR=1.83E-24), LAG3 (FDR=6.91E-21), ICAM1 (FDR=1.41E-11), HLA-
DQA1 (FDR=3.84E-16), HLA-DRA (FDR=3.38E-17), IDO1 (FDR=8.44E-20), and 
GZMA (FDR=3.34E-18) (Figure 8A and Supplementary Table 12). More specifically, 
immune inhibitors with the greatest differences between subtypes included PDL-1, PD1, 
CTLA-4, IDO1, or LAG3, and were most highly expressed in the IFN-γ Dominant 
subtype (Figure 8B).  Significant differences observed between the 2 major immune 
phenotypes, Wound Healing and IFN-γ Dominant subtypes, were maintained within each 
CMS subgroup (Supplementary Figure 11).  
 
Copy-number variations affected multiple IMs and both amplifications and 
deletions were frequently found in the Wound Healing subtype, while other immune 
subtypes showed fewer alterations (Figure 8A). Thus, SLAMF4, TNFSF4, CX3CL1, 
IL10, IL2, ENDRB, CD40, IDO1 and HMG β1 genes were most frequently amplified, 
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while VTCN1, CD276 (PDL-1), IL4, IL13, TNGRS-F18, -F4,-F9, -14 and ADORA2A 
were most frequently deleted. Overall, these observations are very relevant for cancer 
immunotherapy as numerous IM agonists and antagonists are currently under clinical 
development29 . Moreover, there were significant differences in tumor mutational burden 
(TMB) which is larger in IFN-γ Dominant subtype. However, when we look at CMS1 
cohort not differences were found between Wound Healing and in IFN-γ Dominant 
subtype. Related to B cell receptors (BCR), Lymphocyte Depleted subtype has less 
richness that the others. The same happens with T cell receptors (TCR) which are more 
richness in Inflammatory subtype.  
In summary immunomodulatory genes are more expressed in IFN-γ subtype than 
in Wound Healing subtype while the opposite occurs with the alterations in these genes. 
However, IFN-γ is the subtype with more TMB, being not maintaining when we analysed 
each CMS. 
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Figure 8: Expression and CNV of immune modulators (IM), tumor mutational burden 
(TMB), B cell receptor (BCR) and T cell receptor (TCR) diversity by immune subtypes. A) 
Heatmap showing median of log 2 normalized mRNA Z-score expression, amplification 
frequency (the difference between the fraction of samples in which an IM is amplified in a 
particular subtype and the amplification fraction in all samples); and the deletion frequency (as 
amplifications) for 75 IM genes by immune subtype. B) Expression levels of immune-
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checkpoints; p value was computed using Kruskal-Wallis test. TMB, BCR Richness and TCR 
Richness were represented by immune subtypes and p values were computed by Wilcox rank test 
(*P<0.05, **P< 0.01, ***P<0.001, **** P<0.0001). Number of patients with gene expression 
data for each immune subtype is detailed below the bar plots.  
 
 
4.7 Differential gene expression signatures between Wound Healing and IFN-γ Dominant 
subtypes identify key genes and pathways of potential diagnostic or therapeutic relevance 
in CRC patients 
We analysed gene expression profiles of the 2 major ISs in CRC (Wound Healing 
and IFN-γ Dominant subtypes), both in the global cohort of CRC patients and by CMS to 
address the interplay of both classifications.  3150 and 1362 differentially expressed 
genes achieved statistical significance (FDR< 0.05) when we analysed all and CMS1 
CRC patients, respectively (Figure 9A and      Supplementary results 1-2).  239, 108 and 
327 genes showed significant differential expression when these subtypes (Wound 
Healing and IFN-γ Dominant subtypes) were compared within the CMS2, CMS3 and 
CMS4 groups, respectively (Figure 9A and Supplementary results 3-5).  As shown in 
Figure 9, the expression profile of an important number of genes was specific to each 
CMS, but 21 genes were consistently found to be differentially expressed in all analysis 
performed (Figure 9A and Supplementary Table 13).  
Then, we analysed enrichment score gensets to determine the upregulation of 
relevant pathways within immune subtypes. Analysis of the whole cohort showed that the 
Wound Healing subtype was enriched in metabolic pathways and had greater activation 
of Wnt and hedgehog signalling (Figure 9B). In contrast, the IFN-γ Dominant subtype 
presented greater activation of pathways related to the immune system, apoptosis and 
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DNA repair, as well as mTOR signalling and oxidative phosphorylation (Figure 9B and 
Supplementary Table 14). Similar results were found when CMS1 group was analysed, 
being metabolism related pathways such as glycolysis and pyruvate metabolism 
overrepresented in the Wound Healing subtype, and apoptosis and reactive oxygen 
species pathways characteristic of the IFN-γ Dominant group (Supplementary Figure 12 
and Supplementary Tables 15-18). 
This result suggests that clear biological differences exist between IFN-γ 
Dominant and Wound Healing samples apart from immune system activation. Some of 
these differences such as metabolism, matrix remodeling and other pathways in cancer 
could explain the distinct immune phenotype. 
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 Figure 9: Genes and pathways differentially expressed between wound healing and IFN-γ 
dominant immune subtypes. A) Upset plot showing differentially expressed genes between 
wound healing and IFN-γ dominant immune subtypes in all cohort and in each CMS subtype. B) 
Heatmap showing the Gene set mRNA enrichment analysis (ssGSEA) of signatures (median z -
scores) of special interest in CRC among the 2 predominant immune subtypes, wound healing 
and IFN-γ dominant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
 
5. Discussion 
An increasing body of evidence supports the major role that tumor 
microenvironment and, in particular, the immune system plays in cancer fate52. An 
improved understanding of the immune landscape of tumors is, therefore, critical to refine 
immunotherapeutic strategies that have actually revolutionized cancer care but are still 
ineffective in a great proportion of CRC patients. Besides, nowadays only few molecular 
biomarkers are considered and in many cases are used separately. The advances in the 
sequencing technology will provide more accurate expression data, that have the potential 
to describe the microenvironment status using many information together. In this way, 
Thorsson et al. have described six immune subtypes that encompass nearly all human 
malignancies, with distinct immunogenomic features and a significant impact in clinical 
outcome16. Nevertheless, the distribution of these immune subtypes substantially differed 
across the 33 solid tumors included, and it seems that their association with patients’ 
prognosis was also dependent on tumor type. 
In the present study, we have specifically characterized the immune subtypes in 
the  TCGA cohort of CRC patients, including clinical and pathological features, genomic 
and transcriptomic profiles, and composition and functional orientation of the immune 
and stromal cell components of tumor microenvironment. In our study we show that 
among CRC patients only 5 of the 6 immune subtypes are present, with 2 predominant 
ISs: the C1 Wound Healing subtype, identified in 459 samples (77%), and the C2 IFN-γ 
Dominant subtype, present in 103 samples (17%). The other 3 ISs were far less commonly 
encountered in CRC (C3 Inflammatory: 18 samples, 3%; C4 Lymphocyte Depleted: 13 
samples, 2%; and C6 TGF-β Dominant: 4 samples, 0.7%). This result suggests that there 
is not a lot heterogeneity in an immune point of view in colorectal cancer and only a 23% 
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of patients belong to another group that is not the principal IS.  Nevertheless, the fact that 
this classification is made in several solid tumors could dilute existing differences in this 
specific tissue but at the same time it makes the groups more robust and, in theory, with 
more remarkable differences among them.  
We have also studied the interplay between IS classification and CMS 
classification15 . We could see that these both classification systems had related each to 
other with clearly enrichments, but do not overlap completely. Indeed, the C1 Wound 
Healing IS was particularly dominant in CMS2 (91%) but far less common in CMS1 
(46%) tumors, whereas the proportion of C1 Wound Healing in CMS3 and CMS4 tumors 
was similar to the average observed for the overall CRC population (77-78%). On the 
contrary, the C2 IFN-γ Dominant was the most common IS observed in CMS1 tumors 
(53%) and was under-represented in CMS2 tumors (8%), with a slightly higher 
representation in CMS3 and CMS4 tumors (11-13%). Other ISs were barely present in 
CMS1 and CMS2 tumors, whereas the immunological landscape of CMS3 and CMS4 
was more diverse: they had some representation of the C3 Inflammatory (7% and 6%, 
respectively) and C4 Lymphocyte Depleted (4.3% and 1.5%, respectively) subtypes, and 
all 3 cases with the TGF-β Dominant phenotype belonged exclusively to the CMS4 
subgroup (2.3%) . This result could contrast with the idea that CMSs are homogenous 
groups in an immune point of view with a potential predictor power to immunotherapy 
response2,7,33,53–55. Thus, it leads us to wonder what information could provide IS 
classification to the well-known CMS classification.   
First, we looked for enrichments in several molecular and clinical features in the 
different IS, founding some of them with significance. However, this significance 
disappeared in the analysis made in each subtype. This suggest that differences in the 
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whole cohort among IS are provided by the enrichment in the distinct CMS but not by 
itself. Nevertheless, it seems to have importance in the prognosis when   Cox multivariate 
regression showed that the IS classification was significantly associated with survival in 
CRC patients, independent of other well-established prognostic factors including age, 
stage at diagnosis and primary tumor site, whereas the CMS classification lost statistical 
significance in the multivariate analysis. These observations could be consistent with the 
fact that biological differences were found among immune subtypes, even inside each 
CMS subtype. For instance, CMS1(MSI-like Immune) showed clear dissimilarities 
between C1 wound healing subtype and C2 IFN-γ dominant subtype. To date, CMS1  
patients had been postulated to be the most likely to benefit from immune-checkpoint 
inhibitors, as this subtype includes most MSI tumors, which are highly mutated tumors 
due to deficient DNA mismatch repair mechanisms56,57. Nevertheless, not all CMS1 are 
MSI tumors and other CMS subgroups (i.e, CMS3) also include a significant proportion 
of MSI patients. This is relevant as MSI is the biomarker used in pivotal studies that 
demonstrated the clinical efficacy of checkpoint inhibitors in CRC, and the only available 
biomarker in standard clinical practice to identify immunogenic CRC17–20,23. Indeed, MSI 
has been the first biomarker to define a Food and Drug Administration (FDA) approval 
of an anticancer drug (pembrolizumab) for a tumor/site-agnostic indication58.  Moreover, 
our results reported that the immunotherapy landscape of CMS1 is diverse and this may 
potentially impact response to therapy. Given the fact that IFN-γ Dominant tumors 
presented a high expression of CD8+, follicular helper T cells and M1 macrophages, as 
well as high levels of regulatory T cells, M2 macrophages, dendritic cells and neutrophils, 
and this IS was also characterized by the upregulation of several immune regulatory genes 
(PD-1/PD-L1, CTLA4, IDO1 and LAG3) likely responsible for its immune surveillance 
escape mechanism, we could hypothesize that the IFN-γ Dominant IS may be responsible 
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in part of  the heavy immune activation and  susceptibility of CMS1 tumors to immune-
checkpoint inhibition, whereas CMS1 tumors of the Wound Healing subtype may likely 
be less immunogenic and more resistant to these agents and require other therapeutic 
approaches. In addition, IFN-γ Dominant tumors belonging to CMS2-4 subgroups could 
also potentially benefit of immune-checkpoint targeted therapy. This is particularly 
relevant as MSI tumors only represent a small proportion of patients with advanced CRC 
(5%), and despite the unquestionable success of immunotherapy in this subgroup of 
patients, still a significant proportion of MSI tumors (40-60%) do not respond to 
checkpoint inhibitors for yet unexplored biological grounds. On the contrary, a subset of 
MSS tumors also show increased expression of immune genes, indicating that other 
factors also determine immune infiltration and clinical outcome. In fact, some immune 
profiles such as the CRC immunescore59, based on the histological quantitation and 
localization of cytotoxic and memory T cells in the tumor center and invasive margin, 
proved to be a stronger predictor of patient survival than MSI60. The new IS classification 
could be therefore a new valuable tool to aid in the selection of patients for immune 
therapy.  
Another relevant finding of our study was that the prognostic impact of immune 
subtypes in CRC patients was different from that reported for the global TCGA dataset16. 
Considering the two most prevalent IS in CRC, it is to be noted that differences in survival 
between the Wound Healing and IFN-γ Dominant subtypes were more pronounced as 
compared to the overall cancer population including all solid tumors.  IFN-γ is a cytokine 
mainly produced by activated T lymphocytes and by natural killer cells in response to a 
variety of immune stimuli. The activation of IFN-γ pathway directly results in the 
inhibition of tumor cell growth and the improvement of immune response, which 
recognizes and eliminates tumor cells. Specifically in CRC, IFN-γ induces tumor cell 
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cycle arrest by enhancing expression of p27, p16 or p2161 and autophagy-associated 
apoptosis62. However, the pro-tumoral functions of IFN-γ involve proliferative and anti-
apoptotic signals, as well as cancer evasion by promoting angiogenesis or the expression 
of immune-checkpoints63,64. Particularly, several reports have demonstrated that IFN-γ 
induce the expression of PDL-1, IDO and CTL-4 in tumor cells and were associated with 
poor prognosis in several cancer types63.   
Some of these observations may be partially conditioned by some relevant caveats 
inherent to the use of TCGA data. First, the fact that for most tumor types a tumor cell 
component > 50% was required for study entry; this introduces a significant bias as the 
epithelial cell component is likely over-represented and the most immune-infiltrated 
tumors are excluded from the analysis. In addition, survival rates and patient follow-up 
substantially differed across tumor types, antitumor therapy is presumably very 
heterogeneous in the study population, and its impact on clinical outcome is not 
considered.  
Finally, it should be pointed out that the IS classification was developed in a large 
but very heterogeneous cancer population, which may dilute distinct transcriptomics 
profiles within each tumor type with potentially relevant clinical implications. This is also 
reflected in the lack of high variance in immune subtypes between CMS4 and CMS3 
when immunogenic differences were found in previous publications33. Thus, further 
refinement of this classification specifically adjusted for CRC is certainly warranted. 
Moreover, we did not find the same biologic differences between Wound healing and 
IFN-γ dominant in all CMS. Starting by immune population, we could see that IFN-γ 
dominant in CMS1 is enriched in several immune populations while in other subtypes it 
is not happen, despite of in all CMS are differences in the expression of interferon gamma 
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and alpha between the principal ISs. Furthermore, not all genes are differentially 
expressed between Wound Healing and IFN-γ dominant in all CMS, existing genes only 
found in one of them. We are probably facing a different molecular scenario where IFN-
γ is differentially activated in all of them, but with distinct biological meanings. Besides, 
is interesting to study what could be underlying these differences in the expression of 
IFN-γ. The presence of T cells and Natural killer cells populations infiltrated in the tumor 
has been recently associated with the TMB, which increase the probability to a neoantigen 
would be recognized promoting the expression of cytokines64. However, we did not see 
such variations inside each CMS cohort, what means that other processes are involved. 
For instance, some of the genes differentially expressed between Wound Healing and 
IFN-γ Dominant in CMS1 are related to proteasome and immunoproteasome (PSME2 
FDR = 0.01 E-4; PSME1 FDR= 0.005; PSMB8; FDR = 0.01; PSMB10 FDR= 0.01; 
PSMA4 FDR = 0.01; PSMB9 FDR = 0.02; PSMA6; FDR= 0.02; PSMA1 FDR = 0.043 ) 
(Supplementary results 2). Immunoproteasome is necessary to process mutated proteins 
in peptides to be presented so the incorrect function of this complex do not allow that 
peptides could be presented by molecular histocompatibility complex (MHC). The lack 
of IFN-γ in Wound Healing tumors could be the cause of this down expression, since it 
is well known that this is the main cytokine which promote proteasome related genes. 
Furthermore, we could find overexpressed genes in Wound Healing samples that inhibit 
different aspects of immune response (GP2 FDR = 6E-6; FGL1 FDR = 5E-4; SPINK4 
FDR = 0.04) (Supplementary results 2). GP2  reduced innate and adaptive immune 
responses at several levels, FGL1 is a known ligand of LAG3 promoting the inhibition of 
T cells and  SPINK4 that encodes for a serine peptidase inhibitor that has been associated 
to inhibit granzymes cytotoxic effect used by CD8+ T and NK cells65–67. On the other 
hand, CMS2 Wound healing samples have an overexpression of LNX1 (FDR = 8.26E-5) 
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which encodes for membrane protein that binds CD8+ T cell protein provoking it is 
ubiquitination and degradation what result in the incorrect function of the 
cell68(Supplementary results 3).  
In summary, in line with the changing treatment paradigm, that is shifting from 
the traditional one predominantly focused on targeting the epithelial compartment, to the 
development of more integrated approaches targeting tumor microenvironment, in-depth 
study of the immune landscape of tumors provides very valuable information for cancer 
management.   
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6. Conclusions 
In the present study we have characterized the recently described pan-cancer IS 
classification in a large cohort of CRC patients, demonstrating distinct clinical and 
biological implications of ISs in this cancer type. We have also identified substantial 
heterogeneity in the distribution of ISs by CMS subgroups. Moreover, we show that IS 
classification identify tumors which have different microenvironments, although belong 
to the same CMS, being interesting to highlight that we can separate the immune 
molecular subtype CMS1 in two different IS with clear immune differences.  It is 
expected that profound biological differences observed among ISs and CMS translate into 
heterogeneous drug responses, both to conventional cytotoxic drugs and alternative 
treatment strategies targeting the tumor ecosystem, including immunotherapy. However, 
this result should be validated in an independent cohort of patients and the clinical 
implications must be tested in clinical trials.  
 
  
43 
 
7. References 
1. Basile, D. et al. Immunotherapy for colorectal cancer: where are we heading? 
Expert Opinion on Biological Therapy 17, 709–721 (2017). 
2. Ciardiello, D. et al. Immunotherapy of colorectal cancer: Challenges for 
therapeutic efficacy. Cancer Treatment Reviews 76, 22–32 (2019). 
3. Lièvre, A. et al. Protein biomarkers predictive for response to anti-EGFR 
treatment in RAS wild-type metastatic colorectal carcinoma. British Journal of Cancer 
117, 1819–1827 (2017). 
4. Ganesh, K. et al. Immunotherapy in colorectal cancer: rationale, challenges and 
potential. Nature Reviews Gastroenterology & Hepatology 16, 361–375 (2019). 
5. Kalyan, A., Kircher, S., Shah, H., Mulcahy, M. & Benson, A. Updates on 
immunotherapy for colorectal cancer. Journal of Gastrointestinal Oncology 9, 160–169 
(2018). 
6. Garrido-Castro, A. C., Lin, N. U. & Polyak, K. Insights into Molecular 
Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for 
Treatment. Cancer Discovery 9, 176–198 (2019). 
7. Dienstmann, R. et al. Consensus molecular subtypes and the evolution of 
precision medicine in colorectal cancer. Nature Reviews Cancer 17, 79–92 (2017). 
8. Collisson, E. A., Bailey, P., Chang, D. K. & Biankin, A. V. Molecular subtypes 
of pancreatic cancer. Nature Reviews Gastroenterology & Hepatology 16, 207–220 
(2019). 
44 
 
9. Budinska, E. et al. Gene expression patterns unveil a new level of molecular 
heterogeneity in colorectal cancer: Gene expression heterogeneity in colorectal cancer. 
The Journal of Pathology 231, 63–76 (2013). 
10. De Sousa E Melo, F. et al. Poor-prognosis colon cancer is defined by a 
molecularly distinct subtype and develops from serrated precursor lesions. Nature 
Medicine 19, 614–618 (2013). 
11. Marisa, L. et al. Gene Expression Classification of Colon Cancer into Molecular 
Subtypes: Characterization, Validation, and Prognostic Value. PLoS Medicine 10, 
e1001453 (2013). 
12. Roepman, P. et al. Colorectal cancer intrinsic subtypes predict chemotherapy 
benefit, deficient mismatch repair and epithelial-to-mesenchymal transition: Molecular 
subtypes in colorectal cancer. International Journal of Cancer 134, 552–562 (2014). 
13. Sadanandam, A. et al. A colorectal cancer classification system that associates 
cellular phenotype and responses to therapy. Nature Medicine 19, 619–625 (2013). 
14. Schlicker, A. et al. Subtypes of primary colorectal tumors correlate with response 
to targeted treatment in colorectal cell lines. BMC Medical Genomics 5, (2012). 
15. Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat Med 
21, 1350–1356 (2015). 
16. Thorsson, V. et al. The Immune Landscape of Cancer. Immunity 48, 812-830.e14 
(2018). 
17. Le, D. T. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New 
England Journal of Medicine 372, 2509–2520 (2015). 
45 
 
18. Imran, A. et al. Role of Molecular Biology in Cancer Treatment: A Review 
Article. Iran. J. Public Health 46, 1475–1485 (2017). 
19. Jasperson, K. W., Tuohy, T. M., Neklason, D. W. & Burt, R. W. Hereditary and 
Familial Colon Cancer. Gastroenterology 138, 2044–2058 (2010). 
20. Cancer Control Opportunities in Low- and Middle-Income Countries. (National 
Academies Press, 2007). doi:10.17226/11797 
21. The Cancer Genome Atlas Research Network et al. The Cancer Genome Atlas 
Pan-Cancer analysis project. Nature Genetics 45, 1113–1120 (2013). 
22. Tamborero, D. et al. Comprehensive identification of mutational cancer driver 
genes across 12 tumor types. Scientific Reports 3, (2013). 
23. Zhu, K. et al. Oncogenes and tumor suppressor genes: comparative genomics and 
network perspectives. BMC Genomics 16 Suppl 7, S8 (2015). 
24. Siegel, R. L. et al. Colorectal cancer statistics, 2017: Colorectal Cancer Statistics, 
2017. CA: A Cancer Journal for Clinicians 67, 177–193 (2017). 
25. Ren, Z. & Tao, Z. Molecular Basis of Colorectal Cancer: Tumor Biology. in 
Surgical Treatment of Colorectal Cancer (eds. Kim, N. K., Sugihara, K. & Liang, J.-T.) 
23–34 (Springer Singapore, 2018). doi:10.1007/978-981-10-5143-2_3 
26. Terry, P. et al. Fruit, Vegetables, Dietary Fiber, and Risk of Colorectal Cancer. 
JNCI Journal of the National Cancer Institute 93, 525–533 (2001). 
27. Han, S. et al. Role of intestinal flora in colorectal cancer from the metabolite 
perspective: a systematic review. Cancer Management and Research Volume 10, 199–
206 (2018). 
46 
 
28. Morán, A. Differential colorectal carcinogenesis: Molecular basis and clinical 
relevance. World Journal of Gastrointestinal Oncology 2, 151 (2010). 
29. Oiseth, S. J. & Aziz, M. S. Cancer immunotherapy: a brief review of the history, 
possibilities, and challenges ahead. Journal of Cancer Metastasis and Treatment 3, 250 
(2017). 
30. Lowe, R., Shirley, N., Bleackley, M., Dolan, S. & Shafee, T. Transcriptomics 
technologies. PLOS Computational Biology 13, e1005457 (2017). 
31. Zhao, S., Fung-Leung, W.-P., Bittner, A., Ngo, K. & Liu, X. Comparison of RNA-
Seq and Microarray in Transcriptome Profiling of Activated T Cells. PLoS ONE 9, 
e78644 (2014). 
32. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based 
approach for interpreting genome-wide expression profiles. Proceedings of the National 
Academy of Sciences 102, 15545–15550 (2005). 
33. Becht, E. et al. Immune and Stromal Classification of Colorectal Cancer Is 
Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clinical 
Cancer Research 22, 4057–4066 (2016). 
34. Roma-Rodrigues, C., Mendes, R., Baptista, P. & Fernandes, A. Targeting Tumor 
Microenvironment for Cancer Therapy. International Journal of Molecular Sciences 20, 
840 (2019). 
35. The Cancer Genome Atlas Network. Comprehensive molecular characterization 
of human colon and rectal cancer. Nature 487, 330–337 (2012). 
36. Goldman, M. et al. The UCSC Xena platform for public and private cancer 
genomics data visualization and interpretation. bioRxiv (2019). doi:10.1101/326470 
47 
 
37. Gao, J. et al. Integrative Analysis of Complex Cancer Genomics and Clinical 
Profiles Using the cBioPortal. Science Signaling 6, pl1–pl1 (2013). 
38. Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with 
high-throughput sequencing data. Bioinformatics 31, 166–169 (2015). 
39. Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of 
the targets of focal somatic copy-number alteration in human cancers. Genome Biology 
12, R41 (2011). 
40. R Development Core Team. R: A Language and Environment for Statistical 
Computing. (R Foundation for Statistical Computing, 2008). 
41. Kaplan, E. L. & Meier, P. Nonparametric Estimation from Incomplete 
Observations. Journal of the American Statistical Association 53, 457 (1958). 
42. Peto, R. et al. Design and analysis of randomized clinical trials requiring 
prolonged observation of each patient. II. Analysis and examples. British Journal of 
Cancer 35, 1–39 (1977). 
43. Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression 
profiles. Nature Methods 12, 453–457 (2015). 
44. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and 
correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849 (2016). 
45. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and 
dispersion for RNA-seq data with DESeq2. Genome Biology 15, (2014). 
46. Yoav Benjamini, Y. H. Controlling the False Discovery Rate: A Practical and 
Powerful Approach to Multiple Testing. J. Royal Stat. Soc. 57, 289–300 (1995). 
48 
 
47. Durinck, S. et al. BioMart and Bioconductor: a powerful link between biological 
databases and microarray data analysis. Bioinformatics 21, 3439–3440 (2005). 
48. Carlson, M. KEGG.db: A set of annotation maps for KEGG. (2016). 
49. Gehlenborg, N. UpSetR: A More Scalable Alternative to Venn and Euler 
Diagrams for Visualizing Intersecting Sets. (2019). 
50. Hänzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for 
microarray and RNA-Seq data. BMC Bioinformatics 14, 7 (2013). 
51. Hervé, M. RVAideMemoire: Testing and Plotting Procedures for Biostatistics. 
(2019). 
52. Wang, M. et al. Role of tumor microenvironment in tumorigenesis. Journal of 
Cancer 8, 761–773 (2017). 
53. Sveen, A. et al. Colorectal Cancer Consensus Molecular Subtypes Translated to 
Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clinical 
Cancer Research 24, 794–806 (2018). 
54. Spallanzani, A. et al. Immunotherapy in the treatment of colorectal cancer: a new 
kid on the block. Journal of Cancer Metastasis and Treatment 4, 28 (2018). 
55. Roelands, J. et al. Immunogenomic Classification of Colorectal Cancer and 
Therapeutic Implications. International Journal of Molecular Sciences 18, 2229 (2017). 
56. Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to 
PD-1 blockade. Science 357, 409–413 (2017). 
49 
 
57. Gelsomino, F., Barbolini, M., Spallanzani, A., Pugliese, G. & Cascinu, S. The 
evolving role of microsatellite instability in colorectal cancer: A review. Cancer 
Treatment Reviews 51, 19–26 (2016). 
58. Lemery, S., Keegan, P. & Pazdur, R. First FDA Approval Agnostic of Cancer Site 
— When a Biomarker Defines the Indication. New England Journal of Medicine 377, 
1409–1412 (2017). 
59. Galon, J. et al. Cancer classification using the Immunoscore: a worldwide task 
force. Journal of Translational Medicine 10, (2012). 
60. Mlecnik, B. et al. Integrative Analyses of Colorectal Cancer Show Immunoscore 
Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity 44, 
698–711 (2016). 
61. Wang, L., Wang, Y., Song, Z., Chu, J. & Qu, X. Deficiency of Interferon-Gamma 
or Its Receptor Promotes Colorectal Cancer Development. Journal of Interferon & 
Cytokine Research 35, 273–280 (2015). 
62. Wang, Q.-S., Shen, S.-Q., Sun, H.-W., Xing, Z.-X. & Yang, H.-L. Interferon-
gamma induces autophagy-associated apoptosis through induction of cPLA2-dependent 
mitochondrial ROS generation in colorectal cancer cells. Biochemical and Biophysical 
Research Communications 498, 1058–1065 (2018). 
63. Seidel, J. A., Otsuka, A. & Kabashima, K. Anti-PD-1 and Anti-CTLA-4 Therapies 
in Cancer: Mechanisms of Action, Efficacy, and Limitations. Frontiers in Oncology 8, 
(2018). 
50 
 
64. McGrail, D. J. et al. Multi-omics analysis reveals neoantigen-independent 
immune cell infiltration in copy-number driven cancers. Nature Communications 9, 
(2018). 
65. Werner, L. et al. Identification of Pancreatic Glycoprotein 2 as an Endogenous 
Immunomodulator of Innate and Adaptive Immune Responses. The Journal of 
Immunology 189, 2774–2783 (2012). 
66. Xie, M., Li, K., Li, J., Lu, D. & Hu, B. Association and diagnostic value of serum 
SPINK4 in colorectal cancer. PeerJ 7, e6679 (2019). 
67. Wang, J. et al. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of 
LAG-3. Cell 176, 334-347.e12 (2019). 
68. D’Agostino, M. et al. Ligand of Numb proteins LNX1p80 and LNX2 interact with 
the human glycoprotein CD8 and promote its ubiquitylation and endocytosis. Journal of 
Cell Science 124, 3545–3556 (2011). 
 
